Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence.
- Resource Type
- Academic Journal
- Authors
- Narain TA; Robotic Pelvic Oncology, Department of Urology, University College London Hospital, London.; Tosh JM; Department of Urology, AIIMS, Rishikesh.; Gautam G; Urological Oncology and Robotic Surgery, Max Institute of Cancer Care, Saket, New Delhi. Electronic address: gagangg@gmail.com.; Talwar HS; Department of Urology, AIIMS, Rishikesh.; Panwar VK; Department of Urology, AIIMS, Rishikesh.; Mittal A; Department of Urology, AIIMS, Rishikesh.; Mandal AK; Department of Urology, AIIMS, Rishikesh.
- Source
- Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE
- Subject
- Language
- English
Neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for muscle invasive non-metastatic bladder cancer patients. While cisplatin based neoadjuvant chemotherapy has been recommended, systemic therapy in a neoadjuvant setting for cisplatin ineligible patients still needs to be addressed. Various strategies like split dosing cisplatin chemotherapy, carboplatin based chemotherapy and taxanes based chemotherapy have been tried as neoadjuvant therapy for cisplatin ineligible patients. Immunotherapy is a promising tool in this regard with a need for the development of predictive and prognostic biomarkers which can bring out the true potential of these immunotherapeutic agents.
(Copyright © 2021 Elsevier Inc. All rights reserved.)